Penmenvy combines the antigenic components of Bexsero (meningococcal Group B vaccine) and Menveo (meningococcal Groups A, C, Y, and W-135 oligosaccharide diphtheria CRM197 conjugate vaccine).
HHS Secretary Robert F. Kennedy Jr. appears to be planning major changes to the way his department oversees vaccines, media ...
Originally scheduled for next week, the meeting of agency advisers will be delayed to give more time for public comment, according to an HHS spokesperson.
Click in for more news from The Hill{beacon} Health Care Health Care The Big Story Key CDC vaccine committee meeting pushed ...
A Centers for Disease Control and Prevention vaccine advisory committee meeting scheduled for next week — the first since ...
A meeting of U.S. vaccine advisers set for late February has been postponed, a federal official confirmed on Thursday, ...
A panel of experts advising the U.S. Centers for Disease Control and Prevention on vaccines will not convene for its February ...
The CDC's Advisory Committee on Immunization Practices was set to meet beginning February 26 and provide recommendations ...
The U.S. Food and Drug Administration has approved Penmenvy (Meningococcal Groups A, B, C, W, and Y Vaccine) for active ...
Penmenvy, which protects against five common types of disease-causing bacteria, is cleared for use in people aged 10 through ...
Thousands of U.S. health agency employees were terminated and told it was for poor performance, though they'd received strong ...
The FDA approved GSK’s pentavalent meningococcal vaccine to protect children and young adults aged 10 to 25 years against ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback